文献速递创伤与烧伤复苏、休克与脓毒症重症综合管理与镇静镇痛

静脉输注间充质基质细胞导致剂量依赖性凝血病且不能减轻大鼠急性创伤性凝血病

Intravenous administration of mesenchymal stromal cells leads to a dose-dependent coagulopathy and is unable to attenuate acute traumatic coagulopathy in rats.
PubMed 文献 · J Trauma Acute Care Surg · 2022-01-01
一句话结论大鼠实验中静脉输注间充质基质细胞(MSCs)呈剂量依赖性凝血病风险,5或10百万/kg BMSCs均不能改善急性创伤性凝血病。

研究检测大鼠骨髓来源(BMSC)与脂肪来源(AMSC)间充质基质细胞的组织因子表达及体外凝血特性,并在健康大鼠和急性创伤性凝血病(ATC)大鼠中评估静脉输注MSCs的凝血影响。健康大鼠静脉输注MSCs后出现剂量依赖性凝血酶原时间延长、血小板计数和纤维蛋白原降低;≤5百万/kg BMSC对止血影响极小。ATC大鼠(多发性创伤+40%失血)伤后1小时静脉输注5或10百万/kg BMSC,凝血酶原时间延长未显著改善;10百万/kg组纤维蛋白原和血小板计数显著降低,乳酸、肺湿/干重比和肺白细胞浸润显著升高。结论认为静脉MSCs有凝血病风险且不能恢复ATC大鼠止血。

要点

  • 健康大鼠静脉输注MSCs后出现剂量依赖性凝血酶原时间延长、血小板计数和纤维蛋白原降低,≤5百万/kg BMSC对止血影响极小。
  • ATC大鼠(多发性创伤+40%失血)伤后1小时静脉输注5或10百万/kg BMSC,凝血酶原时间延长未显著改善。
  • 10百万/kg BMSC组较BMSC-5或载体组纤维蛋白原和血小板计数显著降低,乳酸、肺湿/干重比和肺白细胞浸润显著升高。
  • 静脉输注后MSCs无论剂量均未在循环中发现,而存在于肺内。
  • ATC大鼠BMSC治疗在急性时间范围内免疫或炎症谱未见差异。

适用人群与场景

  • 健康大鼠用于评估静脉输注MSCs的凝血影响;急性创伤性凝血病大鼠(多发性创伤+40%失血)用于评估疗效。
  • 研究场景为大鼠实验,非人类急诊或ICU临床研究。

处置流程与药物剂量

  • 急性创伤性凝血病大鼠在创伤后1小时静脉输注5或10百万/kg BMSCs(BMSC-5、BMSC-10)或载体。

红旗征与不能漏的情况

  • 静脉输注10百万/kg BMSCs可导致纤维蛋白原和血小板计数显著降低,以及乳酸、肺湿/干重比和肺白细胞浸润显著升高。

研究设计与关键结果

  • 大鼠MSCs表达组织因子(TF);大鼠BMSCs或AMSCs与全血体外孵育导致凝血时间显著缩短。
  • 健康大鼠静脉输注MSCs后出现剂量依赖性凝血酶原时间延长、血小板计数和纤维蛋白原降低;≤5百万/kg BMSC对止血影响极小。
  • 静脉输注后无论剂量,MSCs未在循环中发现,而存在于肺内。
  • ATC大鼠中,5或10百万/kg BMSCs未显著影响延长的凝血酶原时间。
  • 10百万/kg BMSC组较BMSC-5或载体组纤维蛋白原和血小板计数显著降低,乳酸、肺湿/干重比和肺白细胞浸润显著升高。
  • ATC大鼠BMSC治疗在急性时间范围内免疫或炎症谱未见差异。

证据类型、等级与局限

  • 证据类型:大鼠实验研究(动物实验)。
  • 局限:原文未报告局限性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Mesenchymal stromal cells (MSCs) express surface tissue factor (TF), which may affect hemostasis and detract from therapeutic outcomes of MSCs if administered intravenously. In this study, we determine a safe dose of MSCs for intravenous (IV) administration and further demonstrate the impact of IV-MSC on acute traumatic coagulopathy (ATC) in rats.

METHODS: Tissue factor expression of rat bone marrow-derived mesenchymal stromal cell (BMSC) or adipose-derived mesenchymal stromal cell (AMSC) was detected by immunohistochemistry and enzyme-linked immunosorbent assay. The coagulation properties were measured in MSC-treated rat whole blood, and blood samples were collected from rats after IV administration of MSCs. Acute traumatic coagulopathy rats underwent polytrauma and 40% hemorrhage, followed by IV administration of 5 or 10 million/kg BMSCs (BMSC-5, BMSC-10), or vehicle at 1 hour after trauma.

RESULTS: Rat MSCs expressed TF, and incubation of rat BMSCs or AMSCs with whole blood in vitro led to a significantly shortened clotting time. However, a dose-dependent prolongation of prothrombin time with reduction in platelet counts and fibrinogen was found in healthy rat treated with IV-MSCs. Bone marrow-derived mesenchymal stromal cells at 5 million/kg or less led to minimal effect on hemostasis. Mesenchymal stromal cells were not found in circulation but in the lungs after IV administration regardless of the dosage. Acute traumatic coagulopathy with prolonged prothrombin time was not significantly affected by 5 or 10 million/kg BMSCs. Intravenous administration of 10 million/kg BMSCs led to significantly lower fibrinogen and platelet counts, while significantly higher levels of lactate, wet/dry weight ratio, and leukocyte infiltration in the lung were present compared with BMSC-5 or vehicle. No differences were seen in immune or inflammatory profiles with BMSC treatment in ATC rats, at least in the acute timeframe.

CONCLUSION: Intravenous administration of MSCs leads to a risk of coagulopathy associated with a dose-dependent reduction in platelet counts and fibrinogen and is incapable of restoring hemostasis of rats with ATC after polytrauma and hemorrhagic shock.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Wu X, Darlington DN, Christy BA, et al. Intravenous administration of mesenchymal stromal cells leads to a dose-dependent coagulopathy and is unable to attenuate acute traumatic coagulopathy in rats. J Trauma Acute Care Surg. 2022. PMID: 34797814. doi:10.1097/TA.0000000000003476

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。